Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending September 2011. The report details a specific corporate action regarding the repurchase and cancellation of the company's ordinary shares, executed in accordance with shareholder authority granted at the Annual General Meeting on May 5, 2011.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share capital transactions.
- Shares Repurchased: 1,500,000 ordinary shares of 25 pence each.
- Transaction Date: September 12, 2011.
- Price Range: Highest price paid was 1,288.5 pence per share; lowest price paid was 1,259.5 pence per share.
- Treasury Holdings: Following cancellation, GSK holds 505,396,816 shares in Treasury.
- Treasury Percentage: Represents 9.06% of total issued share capital and 9.97% of total voting rights.
- Shares in Issue: 5,071,002,941 shares (excluding Treasury shares).
Material Changes
The primary material change reported is the reduction of the company's issued share capital through the cancellation of 1,500,000 repurchased shares. Consequently, the total number of shares in issue decreased to 5,071,002,941. The filing does not provide comparative data against prior periods for financial performance.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook for future periods. It includes a standard disclaimer stating that the announcement does not constitute an offer or solicitation to purchase securities and is made in conformity with the Financial Services Authority's Disclosure and Transparency Rules. No specific risks or contingencies are detailed in this text.
Investor Verification Checklist
- Verify the total number of shares in issue (5,071,002,941) for calculating ownership thresholds under Disclosure and Transparency Rules.
- Confirm the updated Treasury share count (505,396,816) and its impact on voting rights (9.97%).
- Review the price paid per share (1,259.5 to 1,288.5 pence) to assess the cost of capital return relative to market prices on September 12, 2011.
- Note that this filing does not contain quarterly or annual financial results; refer to Form 20-F for comprehensive financial data.